Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total transaction of $821,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, January 23rd, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.26, for a total value of $805,200.00.
• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.52, for a total value of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total value of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Up 1.4%

Royalty Pharma stock opened at $42.97 on Wednesday. The company has a market capitalization of $24.80 billion, a PE ratio of 32.55, a price-to-earnings-growth ratio of 1.62 and a beta of 0.42. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $43.07. The firm has a 50 day moving average price of $39.66 and a 200 day moving average price of $37.85.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The business had revenue of $609.29 million during the quarter, compared to analyst estimates of $765.01 million. Research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be issued a dividend of $0.235 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a yield of 2.2%. Royalty Pharma’s dividend payout ratio (DPR) is 66.67%.

Institutional Trading of Royalty Pharma

Institutional investors have recently bought and sold shares of the business. Capital International Investors raised its position in shares of Royalty Pharma by 24.4% during the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock worth $960,064,000 after acquiring an additional 5,332,074 shares in the last quarter. Swedbank AB increased its stake in Royalty Pharma by 0.4% in the third quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock valued at $430,426,000 after purchasing an additional 42,800 shares during the last quarter. State Street Corp raised its holdings in Royalty Pharma by 0.8% during the third quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock worth $362,423,000 after purchasing an additional 77,815 shares in the last quarter. Geode Capital Management LLC raised its holdings in Royalty Pharma by 2.2% during the second quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock worth $299,494,000 after purchasing an additional 177,036 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Royalty Pharma during the 2nd quarter worth approximately $181,388,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on RPRX. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Citigroup increased their price objective on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Leerink Partners set a $45.00 target price on Royalty Pharma in a research note on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.50.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.